This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
by Indrajit Bandyopadhyay
Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.
Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform is driving rapid growth, but cost optimization could be the key to turning it from a margin drag to a margin lever.
MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G
by Zacks Equity Research
Medtronic secures FDA milestones for its MiniMed 780G system, expanding use to type 2 diabetes and enabling sensor integration.
ISRG's SP Stapler: A Game Changer for Colorectal and Thoracic Procedures?
by Indrajit Bandyopadhyay
Intuitive Surgical's new SP stapler opens doors to colorectal and thoracic surgeries, potentially transforming the single-port platform's adoption curve.
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ISRG vs. MDT: Which MedTech Titan Is the Stronger Investment Choice Now?
by Indrajit Bandyopadhyay
ISRG's strong double-digit robotic growth stands in contrast to MDT's diversified portfolio and more attractive valuation, setting up a compelling medtech comparison.
Here's Why Medtronic (MDT) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Stryker's Robotics and Global Gains Offset by Macro Concerns
by Zacks Equity Research
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
DexCom Expands Access and Innovation While Balancing Headwinds
by Zacks Equity Research
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Why Medtronic (MDT) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Company News for Aug 20, 2025
by Zacks Equity Research
Companies in The News Are: MDT, PINC, PLD, PANW
MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up
by Zacks Equity Research
Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.
Medtronic (MDT) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ISRG's International Push for Ion: Strategic Bet or Overstretch?
by Indrajit Bandyopadhyay
Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.
Medtronic (MDT) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of +2.44% and +2.50%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
by Zacks Equity Research
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -200.00% and -23.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $91.98, denoting a -1% move from the preceding trading day.
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.
Abbott Taps Growing TMVR Market With Tendyne System
by Sridatri Sarkar
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?
by Sridatri Sarkar
Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
by Kinjel Shah
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.